Рекомендованная цена на противоковидное лекарство от Pfizer снижена на 80%

Stock Market News

20 декабря 2022, 22:31

Влиятельная группа, проводящая исследования цен на лекарства, снизила рекомендуемый диапазон цен на противовирусное лекарство от COVID-19 Paxlovid от компании Pfizer Inc более чем на 80%, отчасти из-за снижения тяжести болезни, поскольку штамм коронавируса омикрон имеет тенденцию вызывать менее серьезные заболевания. Институт клинического и экономического обзора (ICER) заявил во вторник, что его новая рекомендованная цена на препарат находится в диапазоне от 563 до 906 долларов за курс лечения. Предыдущая оценка составляла от 3600 до 5800 долларов за курс. ICER не является государственным органом и не имеет права устанавливать цены. Однако многие крупные медицинские страховые компании учитывают их отчеты, когда договариваются о ценах с производителями лекарств.

16, Dostyk street, integral non-residential facility No.2, Yessil district Astana, Republic of Kazakhstan (Talan Towers Offices).

+7 7172 67 77 55 - Free from landline numbers in Kazakhstan; calls from international and mobile numbers are chargeable.

7555 - free from mobile operators in Kazakhstan [email protected], [email protected]

Notify about fraudulent activities or security issues regarding this resource: fbroker.kz/trustcenter

Owning securities and other financial instruments is always associated with risks: the value of securities and other financial instruments can both rise and fall. Past investment results do not guarantee future income. In accordance with the law, the company does not guarantee or promise future returns on investments, nor does it provide guarantees regarding the reliability of potential investments or the stability of potential income.

Freedom Finance Global PLC provides brokerage (agency) services in the securities market on the territory of the Astana International Financial Center (hereinafter referred to as AFSA) in the Republic of Kazakhstan. Subject to compliance with requirements, conditions, restrictions and/or directions of the Acting Law of the AFSA, the Company is authorized to conduct the following Regulated Activities under License No. AFSA-A-LA-2020-0019: Dealing in Investments as Principal, Dealing in Investments as Agent, Managing Investments, Advising on Investments, Arranging Deals in Investments.

S&P Global ratings – “BB-”, outlook “Stable”.

Ownership of securities and other financial instruments always involves risks: the cost of securities and other financial instruments may rise or fall. Past investment results do not guarantee future returns. In accordance with the legislation, the company does not guarantee or promise the profitability of investments in the future, does not guarantee the reliability of possible investments and the stability of the amount of possible income.

The information on the website is updated as part of keeping the data up-to-date and meeting regulatory disclosure requirements. Please note that these updates are for informational purposes only and are not marketing materials!